Biotechnology company developing an oral enzyme therapeutic for celiac disease
Biotechnology company developing an oral enzyme therapeutic for celiac disease. Its candidate is designed to break down immunoreactive gluten in the stomach, potentially preventing symptoms and intestinal damage from accidental gluten ingestion. The technology originated at the University of Washington's Institute for Protein Design and was exclusively licensed to PvP Biologics. Takeda acquired the company in 2020 following promising early clinical results.